



(51) International Patent Classification:

A61K 47/60 (2017.01) C07K 16/32 (2006.01)
A61K 47/65 (2017.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/US2022/025610

(22) International Filing Date:

20 April 2022 (20.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/177,218 20 April 2021 (20.04.2021) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: MOQUIST, Philip; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). LEVEN-GOOD, Matthew R.; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). LEISKE, Christopher I.; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). BINDMAN, Noah A.; c/o Seagen

Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US).

(74) Agent: HARWOOD, Melissa M. et al.; DLA Piper LLP, 701 Fifth Avenue, Suite 6900, Seattle, Washington 98104-7029 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY




FIG. 21

(57) Abstract: The present disclosure provides, inter alia, antibodies with covalently attached biocompatible polymeric moieties, that are useful in treating various diseases such as cancer and autoimmune disorders.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*